MRS and Medication Response: A Pilot Study (NCT03254342) | Clinical Trial Compass
TerminatedNot Applicable
MRS and Medication Response: A Pilot Study
Stopped: Unable to obtain a reliable MRS signal
United States3 participantsStarted 2013-08-06
Plain-language summary
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
Who can participate
Age range21 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. DSM diagnosis of Major Depressive Disorder
✓. Taking paroxetine \[(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)\]for at least 6 weeks
✓. Between 21 - 75 years of age.
✓. Taking a stable dose of paroxetine \[(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)\] for at least the 2 weeks prior to the imaging session
✓. Between 21 - 75 years of age.
✓. Have a 21-item HAM-D score of less than or equal to 5.
✓. No current, or history of any Axis I disorder.
Exclusion criteria
✕. Contraindications for an MRI exam. These includes biomedical devices such as pacemakers, aneurysm clips, prostheses, and other metallic objects embedded in the body such as bullets, buckshot, shrapnel, and any metal fragments from working around metal.
✕. Current pregnancy or lactation.
✕. Patients with claustrophobia.
✕. History, or current Axis I or Axis II disorders
✕. Active unstable medical problems, as confirmed by screening procedures
✕. Diagnosed with any autoimmune disease, (e.g., rheumatoid arthritis, Lupus, MLS).
What they're measuring
1
Measurement of paroxetine (Paxil), citalopram (Celexa) or escitalopram (Lexapro) brain concentrations.